Navigation Links
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
Date:9/17/2007

both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which a Phase 2 clinical trial is underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and three partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, and inflammatory disease. Four additional partnered compounds are in preclinical development. Pharmacopeia's current strategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.

Contact: Amy P. Sharpless

Investor Relations Coordinator

(609) 452-3643

ir_pr@pharmacopeia.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected ou
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... WOONSOCKET, R.I. , Aug. 21, 2014 CVS ... early tender results, applicable Reference Yields and consideration payable in ... Offers") commenced on August 7, 2014 for (1) any and ... and All Notes") and (2) up to a maximum amount ... due 2041 and 5.750% Senior Notes due 2017 (collectively, the ...
(Date:8/21/2014)... ANDOVER, Mass. , Aug. 21, 2014 /PRNewswire/ ... AEX: PHIA) today announced it has received ... Administration to market its precision planning application for ... the Philips TAVI application provides interventionalists with pre-procedural, ... The Philips TAVI planning application is available ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
(Date:8/21/2014)... diabetic peripheral neuropathy is important for the successful ... Fourth Affiliated Hospital of Kunming Medical University, China, ... a sensitive index for nerve conduction studies in ... patients with diabetes mellitus. Nerve conduction studies revealed ... conduction velocity was slower, and sensory nerve action ...
(Date:8/21/2014)... Bedros Keuilian’s Annual Fitness Business Summit is ... by many people already earning seven-figure incomes. But his annual ... only open to the owners of Keuilian’s own international fitness ... Fit Body Boot Camp World Conference will also be attended ... boot camp or are struggling with their own boot ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Quantum ... are pleased to announce the healthcare technology platform, ... operational/production servers. , The company anticipates provisioning its ... are established between individual physicians, via interfaces, to medical ... and finally with electronic data exchanges and medical clearing ...
(Date:8/21/2014)... August 21, 2014 Australian scientists say ... Staph bacteria has been used to successfully fight mesothelioma ... article on the new research. Click here to ... of Western Australia treated mesothelioma cells with ... the cancer cells while simultaneously stimulating a stronger anti-tumor ...
(Date:8/21/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national Chief Nurse Executive ... in Valdosta, GA. The top executive search firm ... recently placed more than 900 healthcare executives into organizations. ... organization headquartered in Valdosta, GA., and its four campuses ...
Breaking Medicine News(10 mins):Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 2Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 3Health News:Grace Century’s Electronic Health Records Project, Quantum Innovations, Announces That PWeR® Healthcare Technology Platform is Ready for Deployment 4Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:South Georgia Medical Center Retains B. E. Smith to Recruit New Chief Nurse Executive 2Health News:South Georgia Medical Center Retains B. E. Smith to Recruit New Chief Nurse Executive 3
... trials in humans to treat obesity from a drug derived ... the Managing Director of the company. ,As per ... and each part of the plant has a different effect ... has the power to curb hunger, some other part of ...
... who wear a special kind of no-line bifocal lenses ... who wear more conventional lenses according to a new// ... Ophthalmology & Visual Science (IOVS). ,The ... myopia progression was slower in children wearing progressive-addition lenses ...
... February is National Children's Dental Health Month and as ... its Fifth Annual Give Kids A Smile Day on ... the ADA offers advice for parents and caregivers to ... ,"Preventive dental care has greatly improved the oral health ...
... pill-sized robot that can travel inside your body, can find ... to a computer//. ,After being swallowed, the robot ... Daily Mail. The miniature video camera fitted with the device ... ,The extraordinary invention by Alex Zivanovic of Imperial College, London, ...
... be bustling around hospital wards in as little as ... developed ground-breaking software//. ,The mechanised "nursebots" being ... such as mopping up spillages, taking messages and guiding ... distribute medicines and even monitor the temperature of patients ...
... if its treatment guidelines are followed, the death rate in ... 5%, but it is more common for 20% or over ... the deaths of 1.5 million children every year. ... Professor of Paediatrics in Blantyre, Malawi discusses whether the problem ...
Cached Medicine News:Health News:Good Oral Health Practices Should Begin in Infancy 2Health News:Robot Nurses Ready For Hospitals 'In Three Years' 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Endotracheal Tube Kits (silicone) Magill, ... includes a SidePort™ AutoControl™ airway connector, ... mm ISO connector., ,The wire ... helping to ensure an open airway., ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
Medicine Products: